ALK and non-small cell lung carcinoma: After the discovery of ALK rearrangement in lung cancer, the first-in-class ALK inhibitor crizotinib was shown to be superior to standard first-line chemotherapy in patients with previously untreated advanced ALK-positive NSCLC.25